Dyax - Advancing Novel Biotherapeutics

Dedicated to finding new solutions for patients in need.

Home>Investors>SEC Filings

SEC Filings

Form 8-K
DYAX CORP filed this Form 8-K on Jul 28, 2010
Document Outline
Entire Document (118.9 KB)
Subdocument 1 - 8-K - DYAX CORP. 8-K
Page 1 - UNITED STATES
Page 2 - Item 2.02. Results of Operations and Financial Condition.
Page 3 - SIGNATURE
Page 4 - EXHIBIT INDEX
Subdocument 2 - EX-99.1 - EXHIBIT 99.1
Page 1 - Exhibit 99.1
Page 2 - Webcast and Conference Call
Page 3 - Disclaimer
Page 4 - DYAX CORP.
Page 5 - SELECTED CONSOLIDATED CONDENSED BALANCE SHEET INFORMATION

Stock quote

ExchangeNASDAQ (US Dollar)
Price$2.32
Change (%) Stock is Down 0.03 (1.28%)
See more

IR Tool Kit

E-mail Alerts  E-mail Alerts
IR Contacts  IR Contacts
RSS Feeds  RSS Feeds
Investor Kit  Online Investor Kit

Investor Relations Contacts

Ivana Magovcevic-Liebisch
Executive Vice President Corporate Development and General Counsel
Dyax Corp.
Phone: 617-225-2500


Nicole Jones
Director, Investor Relations and Corporate Communications
Dyax Corp.
Phone: 617-225-2500


JENNIFER VIERA
Manager, Investor Relations and Corporate Communications
Dyax Corp.
Phone: 617-225-2500

See All